Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized double-blind placebo-controlled phase 2 study of evinacumab in persistent hypercholesterolemia despite maximally tolerated lipid-lowering therapy
MOH_2018-04-08_002053Phase 2Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Nov 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of evinacumab in hypercholesterolemia and familial hypercholesterolemia (FH) (7 arms), sponsored by Regeneron Pharmaceuticals. Started Nov 2017; status: completed.
02
Drugs
evinacumab
03
Conditions
hypercholesterolemiafamilial hypercholesterolemia (FH)
Beyond the preview
Go deeper on MOH_2018-04-08_002053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-04-08_002053.